Navigation Links
Treatment Advocates Challenge Patent for New Hepatitis C Drug
Date:11/24/2013

NEW YORK, Nov. 25, 2013 /PRNewswire-USNewswire/ -- The Open Society Foundations today welcomed a challenge in India to Gilead Science's patent application for their new medicine, sofosbuvir, by the Initiative for Medicines, Access & Knowledge.

The challenge, filed last week at the Kolkata Patent Office, would prevent Gilead from holding the monopoly on sofosbuvir's production and pricing. This would allow Indian manufacturers to produce a cheaper generic version of the medicine, a first step toward making it available other low-and middle-income countries.

Treatment with sofosbuvir is shorter than current treatments, has higher cure rates, can be taken orally, and is better tolerated. But these benefits are not the basis for a patent. And in India, the law states that products that are variants of existing chemical compounds are not patentable.

"Sofosbuvir is not innovative enough at the molecular level to warrant a patent," said Els Torreele, Director of the Open Society Foundations' Access to Essential Medicines Initiative. "This is a battle over whether profits or the lives of patients will drive the hepatitis C response."

Sofosbuvir is expected to be approved in the U.S. and in Europe in the coming weeks and could cost around $80,000 for a course of treatment. With 90% of hepatitis C patients living in low-and middle-income countries, this price tag will put the treatment out of reach for most.

"Without generic competition from India, patent-holding companies will be too slow bringing down prices," said Tahir Amin, Director of the Initiative for Medicines, Access & Knowledge. "This medicine is a variant of known compounds, and Indian law will not allow a company to make billions on it."

Dubbed a "viral time bomb" by the World Health Organization, there are an estimated 170 million people living with chronic hepatitis C globally—12 million of whom live in India. The disease infects nearly 4 million people each year and results in 350,000 deaths annually.

The Open Society Foundations is supporting patient groups and treatment advocates to increase access to hepatitis C treatment in many middle income countries—including Georgia, Ukraine, Vietnam, Thailand, Brazil, and Russia—where the price of even current Hepatitis treatments place them beyond reach.

The Open Society Foundations work to build vibrant and tolerant democracies whose governments are accountable to their citizens. Working with local communities in more than 100 countries, the Open Society Foundations support justice and human rights, freedom of expression, and access to public health and education.

The Initiative for Medicines, Access, & Knowledge (I-MAK) is a team of lawyers and scientists increasing access to affordable medicines by making sure the patent system works. Armed with the best evidence, I-MAK gives the public a voice in a system that impacts their health and lives. It is a grantee of the Open Society Foundations.


'/>"/>
SOURCE Open Society Foundations
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Large Vein Occlusive Disease: Diagnosis and Treatment Options to be Presented at the 40th Annual VEITHsymposium in New York
2. Phase IIb Study of Vanoxerine Shows Strong Safety and Statistically Significant Efficacy Signals for Treatment of Atrial Fibrillation
3. FDA Designates MST-188 As An Orphan Drug For Treatment Of Acute Limb Ischemia
4. Shield Therapeutics Files Investigational New Drug Application for ST10 for the Treatment of Iron Deficiency in Chronic Kidney Disease
5. IceCure Medical Ltd. announces treatment of first breast cancer patient using its IceSense3 Cryoablation System at John Wayne Cancer Institute
6. Polaris Group Announces Treatment of First Patient in Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia
7. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
8. B. Braun to Launch New Level of Water Treatment Technology at ASN
9. NPC, UMD Study: Factors That Cause Different Treatment Responses Are Not Well Understood or Studied
10. Upsher-Smith To Present Findings From Global Phase 3 Trial Investigating USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures At 2013 American Epilepsy Society Meeting
11. Sorrento Therapeutics Enters into Antibody and Vaccine Development Alliance for the Prevention and Treatment of Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 23, 2017  Mirabilis Medical, a ... medical technology for non-invasive surgery, announced today CE ... for treatment of uterine fibroids throughout the European ... received approval from the US Food and Drug ... Mirabilis System in the United States.  The Mirabilis ...
(Date:3/24/2017)... , March 24, 2017 ... to develop sutezolid as effective response to infectious disease ... Alliance and the Medicines Patent Pool (MPP) announced a ... antibiotic drug candidate which demonstrated encouraging results in early ... in combination with other TB drugs and follows the ...
(Date:3/23/2017)... 2017 Research and Markets has announced the ... Industry Forecast to 2025" report to their offering. ... The Global Cryostat Market ... the next decade to reach approximately $3.5 billion by 2025. ... all the given segments on global as well as regional levels ...
Breaking Medicine Technology:
(Date:3/23/2017)... , ... March 23, 2017 , ... ... services to their communities, 16 more public health departments have been awarded national ... bring another 4.5 million people into the expanding network of communities across the ...
(Date:3/23/2017)... ... 23, 2017 , ... The IoT (Internet of Things) is revolutionizing the way ... impact on businesses and individual consumers alike. Laboratories can maximize their profit margin ... anywhere from $4 trillion to $11 trillion dollars by the year 2025. McKinsey expects ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... businesses of the Norwalk and Vermillion areas, celebrates the newest charity campaign ... a nonprofit, community-based substance abuse prevention and peer recovery support organization providing ...
(Date:3/23/2017)... ... 23, 2017 , ... The StayWell Company announced today that ... covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease, ... excellent programs for the delivery and improvement of disease management and that meet ...
(Date:3/23/2017)... ... March 23, 2017 , ... The TouchPoint Solution, home of Buzzies ... stress and anxiety. , “Buzzies change the way we interact with stress and ... , Since its launch date in December 2016, The TouchPoint Solution has sold more ...
Breaking Medicine News(10 mins):